COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the ...
7d
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026Budoprutug clinical trials ongoing in pMN, ...
- Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - ...
Doron Therapeutics, a clinical-stage biotechnology company developing novel biologics for musculoskeletal diseases, today announced that the initial patients have been dosed in its Phase 3 clinical ...
Pharmaceutical Technology on MSN
Liberate Bio gains licences for myeloid-specific CAR design patents
The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.
BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results